M08.4A
Pauciarticular juvenile rheumatoid arthritis, other specified site
Clinical Classification Guidelines
Medical Intelligence & Overview
Pauciarticular juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis, is an inflammatory condition that primarily affects children. The term 'pauciarticular' indicates that fewer than five joints are involved. The designation M08.4A refers specifically to cases where the arthritis affects other specified sites beyond the typical joints, which may include the eyes or skin. This form of juvenile rheumatoid arthritis usually appears in children under the age of 16 and can present with various symptoms depending on the affected areas. Early diagnosis and management are essential to prevent potential complications and improve long-term outcomes.
Causes & Symptoms
Clinical Causes: T h e e x a c t c a u s e o f p a u c i a r t i c u l a r j u v e n i l e r h e u m a t o i d a r t h r i t i s r e m a i n s u n k n o w n . H o w e v e r , i t i s b e l i e v e d t o b e a n a u t o i m m u n e d i s o r d e r , w h e r e t h e i m m u n e s y s t e m m i s t a k e n l y t a r g e t s t h e b o d y ' s o w n t i s s u e s . G e n e t i c f a c t o r s m a y a l s o p l a y a r o l e , a s a f a m i l y h i s t o r y o f a u t o i m m u n e d i s e a s e s c a n i n c r e a s e t h e r i s k . E n v i r o n m e n t a l f a c t o r s , s u c h a s i n f e c t i o n s , m i g h t c o n t r i b u t e t o t r i g g e r i n g t h e c o n d i t i o n i n g e n e t i c a l l y p r e d i s p o s e d i n d i v i d u a l s . T h e c o n d i t i o n d o e s n o t r e s u l t f r o m i n f e c t i o n o r t r a u m a .
Key Symptoms: Persistent swelling or stiffness in affected joints, often the knees, ankles, or wrists Limited range of motion in affected joints Swelling or inflammation in other specified organs or tissues, such as the eyes (iritis or uveitis) Pain in the affected areas, which may be mild or severe Fatigue and general malaise Fever and skin rashes, though these are less common in pauciarticular cases Growth disturbances in affected limbs, especially if the joints are inflamed for prolonged periods
Diagnostic & Treatment
Diagnosis Path: Diagnosing pauciarticular juvenile rheumatoid arthritis involves a comprehensive medical evaluation, including: - Physical examination to assess joint swelling, tenderness, and range of motion - Blood tests, such as inflammatory markers (ESR, CRP) and autoimmune antibodies - Imaging studies like X-rays or ultrasounds to evaluate joint damage or inflammation - Eye examinations to check for inflammation or uveitis, which is common in this form of JRA - Exclusion of other causes of joint swelling in children The combination of clinical findings and laboratory results helps healthcare providers arrive at an accurate diagnosis.
Treatment Protocols: Management of pauciarticular juvenile rheumatoid arthritis aims to reduce inflammation, relieve symptoms, and prevent joint damage. Typical treatments include: - Nonsteroidal anti-inflammatory drugs (NSAIDs) to control pain and inflammation - Disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for long-term disease control - Corticosteroids, used cautiously, for rapid suppression of severe inflammation - Regular eye examinations to monitor and treat uveitis if present - Physical and occupational therapy to maintain joint function and mobility - Regular follow-up with healthcare providers to monitor disease progression and treatment side effects Children with this condition often require multidisciplinary care, involving rheumatologists, ophthalmologists, and physiotherapists, to manage various aspects of the disease effectively.
Clinical Advice & FAQs
Billing Guidance
Is M08.4A a billable ICD-10 code?
Yes, M08.4A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M08.4A?
Clinical documentation must specify the nature of Pauciarticular juvenile rheumatoid arthritis, other specified site and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
